Subscribe
Generic selectors
Exact matches only
Search in title
Search in content
Post Type Selectors

Archive

Iovance provides updates on Amtagvi (lifileucel)

Written by | 26 Aug 2025

In its latest (Q2) earnings report, Iovance confirmed plans to reduce its workforce by 19% in a bid to save $100 million in yearly costs due to lower… read more.

Amtagvi (lifileucel) receives Health Canada approval for advanced melanoma – Iovance Biotherapeutics

Written by | 23 Aug 2025

Iovance Biotherapeutics Inc. announced Health Canada has issued a Notice of Compliance with Conditions (NOC/c) for Amtagvi (lifileucel), a tumor-derived autologous T cell immunotherapy. Amtagvi is indicated for… read more.

FDA accepts sBLA for Keytruda in high-risk stage II melanoma – Merck Inc

Written by | 13 Aug 2021

Merck Inc announced that the Phase III KEYNOTE-716 trial investigating Keytruda (pembrolizumab), Merck’s anti-PD-1 therapy, met its primary endpoint of recurrence-free survival (RFS) for the adjuvant treatment of… read more.

Newsletter Icon

Subscribe for our mailing list

If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.

Subscribe

You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.